Larimar Therapeutics/$LRMR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Larimar Therapeutics
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Ticker
$LRMR
Sector
Primary listing
Employees
65
Headquarters
Website
LRMR Metrics
BasicAdvanced
$336M
-
-$1.56
0.94
-
Price and volume
Market cap
$336M
Beta
0.94
52-week high
$8.93
52-week low
$1.61
Average daily volume
1.6M
Financial strength
Current ratio
5.462
Quick ratio
5.198
Long term debt to equity
2.908
Total debt to equity
3.85
Profitability
EBITDA (TTM)
-108.21
Management effectiveness
Return on assets (TTM)
-35.04%
Return on equity (TTM)
-60.25%
Valuation
Price to book
2.1
Price to tangible book (TTM)
2.1
Price to free cash flow (TTM)
-2.713
Free cash flow yield (TTM)
-36.86%
Free cash flow per share (TTM)
-1.449
Growth
Earnings per share change (TTM)
37.26%
3-year earnings per share growth (CAGR)
-13.05%
What the Analysts think about LRMR
Analyst ratings (Buy, Hold, Sell) for Larimar Therapeutics stock.
Bulls say / Bears say
Deerfield Management, the company’s largest shareholder, showed interest in acquiring shares in the recent equity raise, demonstrating strong insider confidence in the advancement of nomlabofusp.
All 12 analysts covering Larimar have Buy ratings and a median price target of $18, suggesting considerable upside from current price levels.
Larimar intends to use the net proceeds to fund development of its lead candidate nomlabofusp and other pipeline programs, supporting continued progress in its rare disease portfolio.
Shares of Larimar Therapeutics dropped 9.6% premarket to $3.19 after the company priced 18.75 million shares at $3.20, raising $60 million in gross proceeds and highlighting significant investor worries over dilution.
The equity offering was carried out at a 9.3% discount to the previous closing price, indicating weak demand and downward pricing pressure for Larimar’s stock.
During after-hours trading, shares declined 10.8% to $3.15 as Larimar announced an offering of common stock and pre-funded warrants, pointing to persistent market skepticism.
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
LRMR Financial Performance
Revenues and expenses
LRMR Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Larimar Therapeutics stock?
Larimar Therapeutics (LRMR) has a market cap of $336M as of September 13, 2025.
What is the P/E ratio for Larimar Therapeutics stock?
The price to earnings (P/E) ratio for Larimar Therapeutics (LRMR) stock is 0 as of September 13, 2025.
Does Larimar Therapeutics stock pay dividends?
No, Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Larimar Therapeutics dividend payment date?
Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Larimar Therapeutics?
Larimar Therapeutics (LRMR) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.